CN1314682C - 抑制由α4整合素调介的白血球粘附的杂环化合物 - Google Patents

抑制由α4整合素调介的白血球粘附的杂环化合物 Download PDF

Info

Publication number
CN1314682C
CN1314682C CNB038115484A CN03811548A CN1314682C CN 1314682 C CN1314682 C CN 1314682C CN B038115484 A CNB038115484 A CN B038115484A CN 03811548 A CN03811548 A CN 03811548A CN 1314682 C CN1314682 C CN 1314682C
Authority
CN
China
Prior art keywords
compound
diethylamino
ylcarbonyloxy
phenylalanine
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038115484A
Other languages
English (en)
Chinese (zh)
Other versions
CN1656090A (zh
Inventor
安德烈·W·康拉迪
克里斯托夫·M·塞姆科
许英姿
弗兰克·斯塔潘贝克
布赖恩·P·斯图皮
珍妮弗·史密斯
尤金·D·托尔塞特
迈克尔·A·普莱斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of CN1656090A publication Critical patent/CN1656090A/zh
Application granted granted Critical
Publication of CN1314682C publication Critical patent/CN1314682C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB038115484A 2002-05-24 2003-05-27 抑制由α4整合素调介的白血球粘附的杂环化合物 Expired - Fee Related CN1314682C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38302002P 2002-05-24 2002-05-24
US60/383,020 2002-05-24

Publications (2)

Publication Number Publication Date
CN1656090A CN1656090A (zh) 2005-08-17
CN1314682C true CN1314682C (zh) 2007-05-09

Family

ID=29584493

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038115484A Expired - Fee Related CN1314682C (zh) 2002-05-24 2003-05-27 抑制由α4整合素调介的白血球粘附的杂环化合物

Country Status (22)

Country Link
US (3) US7026328B2 (enExample)
EP (1) EP1507775B1 (enExample)
JP (1) JP4469715B2 (enExample)
KR (1) KR100978832B1 (enExample)
CN (1) CN1314682C (enExample)
AT (1) ATE419243T1 (enExample)
AU (1) AU2003240823C1 (enExample)
BR (1) BR0308881A (enExample)
CA (1) CA2481926C (enExample)
DE (1) DE60325583D1 (enExample)
DK (1) DK1507775T3 (enExample)
EA (1) EA008256B1 (enExample)
EC (1) ECSP045425A (enExample)
ES (1) ES2320436T3 (enExample)
IL (2) IL164225A0 (enExample)
MX (1) MXPA04010995A (enExample)
NO (1) NO329933B1 (enExample)
NZ (1) NZ535504A (enExample)
TW (1) TWI281470B (enExample)
UA (1) UA76339C2 (enExample)
WO (1) WO2003099809A1 (enExample)
ZA (1) ZA200407590B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE377003T1 (de) * 1999-01-22 2007-11-15 Elan Pharm Inc Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
PE20050232A1 (es) * 2003-06-25 2005-04-01 Elan Pharm Inc Metodo y composiciones para tratar la artritis reumatoide
US7205310B2 (en) 2004-04-30 2007-04-17 Elan Pharmaceuticals, Inc. Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by VLA-4
BRPI0513143A (pt) * 2004-07-08 2008-04-29 Elan Pharm Inc antagonistas de vla-4 multivalentes compreendendo porções poliméricas
NZ563577A (en) * 2005-05-20 2011-04-29 Elan Pharm Inc Imidazolone phenylalanine derivatives as VLA-4 antagonists
CA2851103A1 (en) * 2005-09-29 2007-04-12 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
WO2007041270A1 (en) * 2005-09-29 2007-04-12 Elan Pharmaceuticals, Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
CN101389611B (zh) * 2006-02-27 2012-07-18 伊兰制药公司 抑制由vla-4所介导的白血球粘附的嘧啶磺酰胺化合物
CA3127202A1 (en) 2006-02-28 2007-09-07 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
EP2007392A4 (en) * 2006-02-28 2010-04-07 Elan Pharm Inc METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS
BRPI0708392A2 (pt) 2006-03-03 2011-05-24 Elan Pharm Inc métodos de tratamento de um paciente com uma doença inflamatória ou autoimune com natalizumab e de uso de natalizumab para tratar um paciente com uma doença inflamatória ou autoimune
CA2708262A1 (en) * 2007-12-07 2009-06-18 Elan Pharmaceuticals, Inc. Methods and compositions for treating liquid tumors
EP2085407A1 (en) 2008-02-04 2009-08-05 Sahltech I Göteborg AB Treatment of idiopathic thrombocytopenic purpura
DK2271634T3 (da) * 2008-04-29 2014-05-05 Integrative Res Lab Sweden Ab Modulatorer af dopamin-neurotransmission
US8367836B2 (en) * 2009-04-27 2013-02-05 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
DK4152004T3 (da) 2010-01-11 2025-02-24 Biogen Ma Inc Analyse for jc-virusantistoffer
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
DK2715352T3 (da) 2011-05-31 2019-05-20 Biogen Ma Inc Fremgangsmåde til vurdering af risiko for pml
JP6080521B2 (ja) * 2012-11-30 2017-02-15 インターナショナル・ビジネス・マシーンズ・コーポレーションＩｎｔｅｒｎａｔｉｏｎａｌ Ｂｕｓｉｎｅｓｓ Ｍａｃｈｉｎｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 広域分散医療情報ネットワークのデータ管理機構
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHOD FOR ASSESSING A PML RISK
CA3008023A1 (en) * 2015-12-30 2017-07-06 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
US20220119383A1 (en) 2018-10-30 2022-04-21 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
KR102659859B1 (ko) 2018-10-30 2024-04-25 길리애드 사이언시즈, 인코포레이티드 알파4β7 인테그린의 억제를 위한 화합물
CN109541237A (zh) * 2018-12-28 2019-03-29 吴江近岸蛋白质科技有限公司 纤维连接蛋白的生物学活性测定方法
CN119431230A (zh) 2019-08-14 2025-02-14 吉利德科学公司 用于抑制α4β7整合素的化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A2 (en) * 1988-02-26 1989-08-30 Dana Farber Cancer Institute VLA proteins
CN1182746A (zh) * 1996-11-15 1998-05-27 赫彻斯特股份公司 用作白细胞粘合抑制剂和vla-4拮抗剂的新的杂环化合物
CN1201454A (zh) * 1995-08-30 1998-12-09 G·D·瑟尔公司 间－胍基、脲基、硫脲基或氮杂环氨基苯甲酸衍生物用作整合素拮抗剂

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2525656A1 (de) 1974-06-19 1976-01-15 Sandoz Ag Verfahren zur herstellung neuer heterocyclischer verbindungen
US4104392A (en) * 1974-11-08 1978-08-01 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof, and antithrombotic compositions and methods employing them
US4055651A (en) * 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4096255A (en) 1974-11-08 1978-06-20 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides, and pharmaceutical salts, compositions and methods
US4055636A (en) 1974-11-08 1977-10-25 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4073914A (en) * 1974-11-08 1978-02-14 Mitsubishi Chemical Industries Limited N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4018915A (en) 1976-01-05 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4070457A (en) 1974-11-08 1978-01-24 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4046876A (en) * 1974-11-08 1977-09-06 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4041156A (en) * 1974-11-08 1977-08-09 Mitsubishi Chemical Industries Limited N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
JPS5727454B2 (enExample) * 1975-02-21 1982-06-10
US4036955A (en) 1976-07-22 1977-07-19 Mitsubishi Chemical Industries Ltd. N2 -naphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4018913A (en) * 1976-01-14 1977-04-19 Mitsubishi Chemical Industries Ltd. N2 -alkoxynaphthalenesulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
CA1102316A (en) 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
DE2742173A1 (de) 1977-09-20 1979-03-29 Bayer Ag Phenoxy-pyridinyl(pyrimidinyl)-alkanole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IT1211096B (it) * 1981-08-20 1989-09-29 Lpb Ist Farm Pirimidine e s.triazinici adattivita' ipolipidemizzante.
US4672065A (en) 1982-11-19 1987-06-09 Chevron Research Company N-substituted phenoxyacetamide fungicides
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4565814A (en) 1983-01-28 1986-01-21 Sanofi Pyridazine derivatives having a psychotropic action and compositions
JPS59212480A (ja) 1983-05-17 1984-12-01 Nippon Soda Co Ltd ピリダジン誘導体及び除草剤
DE3322720A1 (de) 1983-06-24 1985-01-03 Chemische Werke Hüls AG, 4370 Marl Verwendung von in 2-stellung mit (substituierten) aminogruppen substituierten 4-dl-alkylester-(alpha)-alaninyl-6-chlor-s-triazinen als herbizide, insbesondere gegen flughafer
US4505910A (en) * 1983-06-30 1985-03-19 American Home Products Corporation Amino-pyrimidine derivatives, compositions and use
NZ210669A (en) 1983-12-27 1988-05-30 Syntex Inc Benzoxazin-4-one derivatives and pharmaceutical compositions
US4595364A (en) * 1984-02-15 1986-06-17 Molten Corp. Dental prosthesis and process for preparing the same
PH22520A (en) * 1984-11-12 1988-10-17 Yamanouchi Pharma Co Ltd Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
US4959364A (en) 1985-02-04 1990-09-25 G. D. Searle & Co. Method of treating inflammation, allergy, asthma and proliferative skin disease using heterocyclic amides
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH0784424B2 (ja) 1987-04-15 1995-09-13 味の素株式会社 チロシン誘導体及びその用途
DE3904931A1 (de) * 1989-02-17 1990-08-23 Bayer Ag Pyridyl-substituierte acrylsaeureester
US5030644A (en) 1989-07-31 1991-07-09 Merck & Co., Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US4992439A (en) * 1990-02-13 1991-02-12 Bristol-Myers Squibb Company Pyridazine carboxylic acids and esters
FR2679903B1 (fr) 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
DE4108029A1 (de) 1991-03-13 1992-09-17 Bayer Ag Triazinyl-substituierte acrylsaeureester
WO1992016549A1 (de) 1991-03-18 1992-10-01 Pentapharm Ag Para-substituierte phenylalanin-derivate
IT1247509B (it) 1991-04-19 1994-12-17 Univ Cagliari Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
WO1993012809A1 (en) 1991-12-24 1993-07-08 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
NZ249789A (en) 1992-03-11 1997-07-27 Narhex Ltd Hydrazine, carbazate and 1,2-diazacyclic derivatives and pharmaceutical compositions
DE4227748A1 (de) 1992-08-21 1994-02-24 Bayer Ag Pyridyloxy-acrylsäureester
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
CA2193508A1 (en) 1994-07-11 1996-01-25 Eugene D. Thorsett Inhibitors of leukocyte adhesion
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
EP0765879B1 (en) * 1995-09-29 2001-02-14 Sankyo Company Limited 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests
DE19536891A1 (de) 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
DE19548709A1 (de) 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
DK0910575T3 (da) 1996-06-21 2003-02-03 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af peptider
SK176898A3 (en) 1996-06-28 1999-05-07 Merck Patent Gmbh Phenylalamine derivatives as integrin inhibitors
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19647317A1 (de) 1996-11-15 1998-05-20 Hoechst Schering Agrevo Gmbh Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
TR199901128T2 (xx) 1996-11-22 1999-07-21 Elan Pharmaceuticals, Inc. N-(aril/heteroarilasetil) amino asit esterler, bunu ihtiva eden farmas�tik bile�imler ve bu t�r bile�ikler kullanarak �-amiloit peptit sal�n�m�n� ve/veya bunun sentezlenmesini inhibe etme y�ntemleri.
AU6264898A (en) 1997-02-04 1998-08-25 Versicor Inc Solid phase and combinatorial library syntheses of 3,1-benzoxazine-4-ones
DE19713000A1 (de) 1997-03-27 1998-10-01 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
EP1001764A4 (en) 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
EP1017382B1 (en) 1997-05-29 2006-03-01 Merck & Co., Inc. (a New Jersey corp.) Biarylalkanoic acids as cell adhesion inhibitors
KR20010022406A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Ｖｌａ-4에 의해 매개되는 백혈구 유착을 억제하는디펩타이드 및 관련 화합물
CA2290747A1 (en) 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
CA2290746A1 (en) 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
BR9811988A (pt) 1997-08-22 2000-09-05 Hoffmann La Roche Derivados de n-alcanoilfenilalanina
CN100369888C (zh) 1997-08-22 2008-02-20 霍夫曼-拉罗奇有限公司 芳酰基苯丙氨酸衍生物
HUP0100336A3 (en) 1998-01-23 2002-11-28 Novartis Ag Vla-4 antagonists, pharmaceutical compositions comprising them and process for preparing them
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
ID28658A (id) 1998-04-16 2001-06-21 Texas Biotechnology Corp Senyawa yang menghambat pengikatan integrin pada reseptornya
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
WO2000043369A1 (en) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
ATE377003T1 (de) * 1999-01-22 2007-11-15 Elan Pharm Inc Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren
PE20020384A1 (es) * 2000-07-21 2002-05-28 Schering Corp PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A2 (en) * 1988-02-26 1989-08-30 Dana Farber Cancer Institute VLA proteins
CN1201454A (zh) * 1995-08-30 1998-12-09 G·D·瑟尔公司 间－胍基、脲基、硫脲基或氮杂环氨基苯甲酸衍生物用作整合素拮抗剂
CN1182746A (zh) * 1996-11-15 1998-05-27 赫彻斯特股份公司 用作白细胞粘合抑制剂和vla-4拮抗剂的新的杂环化合物

Also Published As

Publication number Publication date
ZA200407590B (en) 2006-10-25
ECSP045425A (es) 2005-03-10
EA200401562A1 (ru) 2005-06-30
KR20050003434A (ko) 2005-01-10
UA76339C2 (en) 2006-07-17
EA008256B1 (ru) 2007-04-27
CN1656090A (zh) 2005-08-17
NO329933B1 (no) 2011-01-24
US7135477B2 (en) 2006-11-14
KR100978832B1 (ko) 2010-08-30
TWI281470B (en) 2007-05-21
EP1507775B1 (en) 2008-12-31
NO20043900L (no) 2004-11-10
US20040138243A1 (en) 2004-07-15
AU2003240823C1 (en) 2009-05-28
JP4469715B2 (ja) 2010-05-26
IL164225A (en) 2010-11-30
DE60325583D1 (de) 2009-02-12
DK1507775T3 (da) 2009-05-11
US20070027131A1 (en) 2007-02-01
US7026328B2 (en) 2006-04-11
AU2003240823B2 (en) 2008-11-06
HK1072608A1 (en) 2005-09-02
TW200400946A (en) 2004-01-16
MXPA04010995A (es) 2005-09-08
AU2003240823A1 (en) 2003-12-12
EP1507775A4 (en) 2006-05-24
CA2481926C (en) 2012-04-24
BR0308881A (pt) 2005-01-11
US7427628B2 (en) 2008-09-23
CA2481926A1 (en) 2003-12-04
NZ535504A (en) 2005-11-25
ES2320436T3 (es) 2009-05-22
IL164225A0 (en) 2005-12-18
JP2005527628A (ja) 2005-09-15
ATE419243T1 (de) 2009-01-15
WO2003099809A1 (en) 2003-12-04
US20050119290A1 (en) 2005-06-02
EP1507775A1 (en) 2005-02-23

Similar Documents

Publication Publication Date Title
CN1314682C (zh) 抑制由α4整合素调介的白血球粘附的杂环化合物
CN1652789A (zh) 抑制由α4整合素介导的白细胞粘附的杂芳基化合物
CN1145609C (zh) 哌嗪化合物及其作为医药的用途
CN1097051C (zh) N－杂芳基吡啶磺酰胺衍生物及其作为内皮素拮抗剂的用途
CN1714084A (zh) 嘧啶－2,4,6－三酮类金属蛋白酶抑制剂
CN1330637A (zh) 用于治疗炎性疾病的化合物
CN1090846A (zh) 嘧啶类化合物和其药用盐的制备方法
CN1113487A (zh) 对中枢神经系统具有药理活性的化合物的制备方法
CN87100707A (zh) 含氮稠合杂环化合物，其制备方法及含有它们的药物配方
CN1788001A (zh) 可用于治疗赘生性疾病、炎性和免疫系统病症的2,4－二(苯氨基)嘧啶
CN1524079A (zh) 新颖的磺酰胺类化合物及其作为内皮素受体拮抗剂的应用
CN1717396A (zh) Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
CN1678613A (zh) 杂芳基腈衍生物
CN1662236A (zh) 组蛋白脱乙酰基转移酶抑制剂
CN1061411A (zh) 用于增强抗肿瘤剂活性的喹唑啉衍生物
CN1053658C (zh) 氨基芪唑衍生物和药
CN1231472C (zh) 嘧啶无环核苷衍生物、其制备方法及其用途
CN1060466A (zh) 苯、吡啶和嘧啶的衍生物
CN1226893A (zh) 精选的K－252a衍生物
CN1753891A (zh) Ccr－3受体拮抗剂
CN1254334A (zh) 新颖的对苯二甲酰胺衍生物
CN1795179A (zh) 新的咪唑衍生物、其制备方法和其作为药物的用途
CN1628103A (zh) 嘧啶衍生物
CN1025617C (zh) 制备嘧啶衍生物及其医药上可用的盐的方法
CN1237161A (zh) 新的氨基醇衍生物、其生产方法以及含有这些化合物的药物制剂和试剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070509

Termination date: 20150527

EXPY Termination of patent right or utility model